Multimodal Management of Desmoplastic Small Round Cell Tumors

Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive malignancy primarily affecting adolescents and young adults, characterised by the hallmark EWSR1–WT1 fusion oncoprotein. Presentation typically involves widespread intra-abdominal disease, with a predilection for serosal surfaces. Traditional management combines multi-agent chemotherapy, aggressive cytoreductive surgery and radiotherapy, yet long-term survival remains dismal. Recent efforts have focused on integrating novel systemic agents, refining surgical techniques and exploring regional therapies to improve outcomes. Advances in molecular profiling have unveiled actionable targets and exposed mechanisms of chemoresistance, while innovations such as hyperthermic intraperitoneal chemotherapy (HIPEC) and targeted immunotherapies are under active investigation. A truly multimodal strategy is emerging, wherein biological insights drive personalised treatment and surgical innovation, offering hope for improved disease control and survival.

Research from Nature Portfolio

Recent studies have demonstrated that second-generation androgen receptor antagonists exert cytotoxic effects in DSRCT cells by mechanisms independent of androgen receptor engagement, suggesting off-target activities that may be repurposed in clinical protocols. This work challenges the prior assumption that male predominance in DSRCT is driven by androgen receptor dependence and opens avenues for combination regimens incorporating these agents. In parallel, comprehensive transcriptomic profiling of patient specimens and cell lines has identified overexpression of growth factors such as IGF2 and FGFR4, alongside immune checkpoint molecules CD200 and CD276, as direct or indirect targets of the EWSR1–WT1 fusion. These findings offer a molecular blueprint for clinical trials of targeted inhibitors and immunomodulatory approaches, laying the groundwork for biomarker-driven therapy in DSRCT.

Multimodal Management of Desmoplastic Small Round Cell Tumors publication trend

The graph below shows the total number of articles in multimodal management of desmoplastic small round cell tumors across all publications each year (not limited to Nature Index journals).

Technical terms

EWSR1–WT1 fusion: A chromosomal translocation creating an oncogenic transcription factor that drives DSRCT development.

Cytoreductive surgery: Aggressive surgical removal of visible tumour deposits to minimise residual disease burden.

Hyperthermic intraperitoneal chemotherapy (HIPEC): Intra-abdominal perfusion of heated cytotoxic agents immediately after cytoreduction to eradicate microscopic cancer cells.

Cancer stem cell-like (CSC-like): A subpopulation of tumour cells with self-renewal capacity and resistance to standard therapies.

Androgen receptor antagonist: A class of drugs that block or modulate the activity of androgen receptors, often used in prostate cancer but repurposed here for DSRCT.

Transcriptomic analysis: Genome-wide measurement of RNA expression to identify dysregulated genes and pathways in tumour cells.

References

1. Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells. Oncogenesis (2024).
2. Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Communications Biology (2024).
3. Intra-Abdominal Desmoplastic Small Round Cell Tumor (DSRCT) and the Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Review. Current Oncology (2023).
4. Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy. Cancers (2021).
5. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis (2020).
6. Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group. Scientific Reports (2020).